MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

184.22 4.16

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

181.73

Massimo

185.05

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+9.27% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

859M

8.8B

Apertura precedente

180.06

Chiusura precedente

184.22

Notizie sul Sentiment di mercato

By Acuity

50%

50%

168 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 apr 2026, 20:26 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 apr 2026, 18:15 UTC

Principali Notizie su Eventi

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 apr 2026, 16:49 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 apr 2026, 16:49 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 apr 2026, 22:58 UTC

Utili

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Discorsi di Mercato

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Utili

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Utili

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 apr 2026, 19:34 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

17 apr 2026, 19:34 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 apr 2026, 19:31 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 apr 2026, 19:26 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up -- Market Talk

17 apr 2026, 19:21 UTC

Discorsi di Mercato

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 apr 2026, 19:15 UTC

Discorsi di Mercato

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr 2026, 19:07 UTC

Discorsi di Mercato

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 apr 2026, 18:57 UTC

Principali Notizie su Eventi

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 apr 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 apr 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

UCB 2026 Rev Guidance Unchanged

17 apr 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 apr 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 apr 2026, 18:14 UTC

Discorsi di Mercato
Principali Notizie su Eventi

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 apr 2026, 18:00 UTC

Principali Notizie su Eventi

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 apr 2026, 18:00 UTC

Principali Notizie su Eventi

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 apr 2026, 17:31 UTC

Discorsi di Mercato
Principali Notizie su Eventi

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 apr 2026, 17:26 UTC

Discorsi di Mercato
Utili

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

9.27% in crescita

Previsioni per 12 mesi

Media 197.3 USD  9.27%

Alto 235 USD

Basso 160 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

11 ratings

7

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

168 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat